Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.

Antibodies, Neoplasm Antigens, Neoplasm Cancer Vaccines Cisplatin Esophageal Neoplasms Esophageal Squamous Cell Carcinoma / drug therapy Fluorouracil Glucans Humans Immunoglobulin A Immunoglobulin G Membrane Proteins Prognosis Receptors, Polymeric Immunoglobulin
Cancer vaccine Esophageal cancer NY-ESO-1 antigen PIGR gene

Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 30 08 2021
accepted: 16 03 2022
pubmed: 17 4 2022
medline: 1 10 2022
entrez: 16 4 2022
Statut: ppublish

Résumé

The aim of this study was to determine the efficacy and the biomarkers of the CHP-NY-ESO-1 vaccine complexed with full-length NY-ESO-1 protein and a cholesteryl pullulan (CHP) in patients with esophageal squamous cell carcinoma (ESCC) after surgery. We conducted a randomized phase II trial. Fifty-four patients with NY-ESO-1-expressing ESCC who underwent radical surgery following cisplatin/5-fluorouracil-based neoadjuvant chemotherapy were assigned to receive either CHP-NY-ESO-1 vaccination or observation as control. Six doses of CHP-NY-ESO-1 were administered subcutaneously once every two weeks, followed by nine more doses once every four weeks. The endpoints were disease-free survival (DFS) and safety. Exploratory analysis of tumor tissues using gene-expression profiles was also performed to seek the biomarker. As there were no serious adverse events in 27 vaccinated patients, we verified the safety of the vaccine. DFS in 2 years were 56.0% and 58.3% in the vaccine arm and in the control, respectively. Twenty-four of 25 patients showed NY-ESO-1-specific IgG responses after vaccination. Analysis of intra-cohort correlations among vaccinated patients revealed that 5% or greater expression of NY-ESO-1 was a favorable factor. Comprehensive analysis of gene expression profiles revealed that the expression of the gene encoding polymeric immunoglobulin receptor (PIGR) in tumors had a significantly favorable impact on outcomes in the vaccinated cohort. The high PIGR-expressing tumors that had higher NY-ESO-1-specific IgA response tended to have favorable prognosis. These results suggest that PIGR would play a major role in tumor immunity in an antigen-specific manner during NY-ESO-1 vaccinations. The IgA response may be relevant.

Identifiants

DOI: 10.1007/s00262-022-03194-5 PMID: 35429246
pubmed: 35429246
doi: 10.1007/s00262-022-03194-5
pii: 10.1007/s00262-022-03194-5
doi:

Substances chimiques

Antibodies, Neoplasm 0
Antigens, Neoplasm 0
Cancer Vaccines 0
Glucans 0
Immunoglobulin A 0
Immunoglobulin G 0
Membrane Proteins 0
Receptors, Polymeric Immunoglobulin 0
pullulan 8ZQ0AYU1TT
Cisplatin Q20Q21Q62J
Fluorouracil U3P01618RT

Types de publication

Clinical Trial, Phase II Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

2743-2755

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : JP17ck0106143

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Boon T (1993) Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 54:177–180. https://doi.org/10.1002/ijc.2910540202
doi: 10.1002/ijc.2910540202 pubmed: 8486420
Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953. https://doi.org/10.1002/ijc.31937
doi: 10.1002/ijc.31937 pubmed: 30350310
Shapiro J, van Lanschot JJB, Hulshof MCCM et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090–1098. https://doi.org/10.1016/S1470-2045(15)00040-6
doi: 10.1016/S1470-2045(15)00040-6 pubmed: 26254683
Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74. https://doi.org/10.1245/s10434-011-2049-9
doi: 10.1245/s10434-011-2049-9 pubmed: 21879261
Mayanagi S, Irino T, Kawakubo H, Kitagawa Y (2019) Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Ann Gastroenterol Surg 3:269–275. https://doi.org/10.1002/ags3.12243
doi: 10.1002/ags3.12243 pubmed: 31131355 pmcid: 6524122
Kelly RJ, Ajani JA, Kuzdzal J et al (2021) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. New Engl J Med 384:1191–1203. https://doi.org/10.1056/NEJMoa2032125
doi: 10.1056/NEJMoa2032125 pubmed: 33789008
Chen YT, Scanlan MJ, Sahin U et al (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914–1918. https://doi.org/10.1073/pnas.94.5.1914
doi: 10.1073/pnas.94.5.1914 pubmed: 9050879 pmcid: 20017
Jungbluth AA, Chen YT, Stockert E et al (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856–860. https://doi.org/10.1002/ijc.1282
doi: 10.1002/ijc.1282 pubmed: 11351307
Gu XG, Schmitt M, Hiasa A et al (1998) A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2- expressing murine sarcomas. Cancer Res 58:3385–3390
pubmed: 9699670
Muraoka D, Harada N, Hayashi T et al (2014) Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity. ACS Nano 8:9209–9218. https://doi.org/10.1021/nn502975r
doi: 10.1021/nn502975r pubmed: 25180962
Ikuta Y, Katayama N, Wang L et al (2002) Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 99:3717–3724. https://doi.org/10.1182/blood.V99.10.3717
doi: 10.1182/blood.V99.10.3717 pubmed: 11986228
Kitano S, Kageyama S, Nagata Y et al (2006) HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res 12:7397–7405. https://doi.org/10.1158/1078-0432.CCR-06-1546
doi: 10.1158/1078-0432.CCR-06-1546 pubmed: 17189412
Kageyama S, Wada H, Muro K et al (2013) Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med 11:246. https://doi.org/10.1186/1479-5876-11-246
doi: 10.1186/1479-5876-11-246 pubmed: 24093426 pmcid: 4015172
Murphy R, Green S, Ritter G et al (2005) Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions. Prep Biochem Biotechnol 35:119–134. https://doi.org/10.1081/PB-200054732
doi: 10.1081/PB-200054732 pubmed: 15881594
Akiyoshi K, Kobayashi S, Shichibe S et al (1998) Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin. J Control Release 54:313–320. https://doi.org/10.1016/S0168-3659(98)00017-0
doi: 10.1016/S0168-3659(98)00017-0 pubmed: 9766251
Stockert E, Jäger E, Chen Y-T et al (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349–1354. https://doi.org/10.1084/jem.187.8.1349
doi: 10.1084/jem.187.8.1349 pubmed: 9547346 pmcid: 2212223
Kaetzel CS (2005) The polymeric immunoglobulin receptor: Bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev 206:83–99. https://doi.org/10.1111/j.0105-2896.2005.00278.x
doi: 10.1111/j.0105-2896.2005.00278.x pubmed: 16048543
Figueiredo DLA, Mamede RCM, Spagnoli GC et al (2011) High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck 33:702–707. https://doi.org/10.1002/hed.21522
doi: 10.1002/hed.21522 pubmed: 20886663
Szender JB, Papanicolau-Sengos A, Eng KH et al (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420–425. https://doi.org/10.1016/j.ygyno.2017.03.509
doi: 10.1016/j.ygyno.2017.03.509 pubmed: 28392127 pmcid: 5497581
Ueda S, Miyahara Y, Nagata Y, Sato E, Shiraishi T, Harada N, Ikeda H, Shiku H, Kageyama S (2018) NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma. Oncotarget 9(89):35997–36011. https://doi.org/10.18632/oncotarget.26323
doi: 10.18632/oncotarget.26323 pubmed: 30542513 pmcid: 6267599
Hayashi M, Takenouchi N, Asano M et al (1997) The polymeric immunoglobulin receptor (secretory component) in a human intestinal epithelial cell line is up-regulated by interleukin-1. Immunology 92:220–225. https://doi.org/10.1046/j.1365-2567.1997.00341.x
doi: 10.1046/j.1365-2567.1997.00341.x pubmed: 9415030 pmcid: 1364062
Piskurich JF, France JA, Tamer CM et al (1993) Interferon-γ induces polymeric immunoglobulin receptor mrna in human intestinal epithelial cells by a protein synthesis dependent mechanism. Mol Immunol 30:413–421. https://doi.org/10.1016/0161-5890(93)90071-I
doi: 10.1016/0161-5890(93)90071-I pubmed: 8455639
Moon C, VanDussen KL, Miyoshi H, Stappenbeck TS (2014) Development of a primary mouse intestinal epithelial cell monolayer culture system to evaluate factors that modulate IgA transcytosis. Mucosal Immunol 7:818–828. https://doi.org/10.1038/mi.2013.98
doi: 10.1038/mi.2013.98 pubmed: 24220295
Kumar P, Monin L, Castillo P et al (2016) Intestinal Interleukin-17 receptor signaling mediates reciprocal control of the gut microbiota and autoimmune inflammation. Immunity 44:659–671. https://doi.org/10.1016/j.immuni.2016.02.007
doi: 10.1016/j.immuni.2016.02.007 pubmed: 26982366 pmcid: 4794750
Fristedt R, Gaber A, Hedner C et al (2014) Expression and prognostic significance of the polymeric immunoglobulin receptor in esophageal and gastric adenocarcinoma. J Transl Med 12:83. https://doi.org/10.1186/1479-5876-12-83
doi: 10.1186/1479-5876-12-83 pubmed: 24694107 pmcid: 4021601
Fristedt R, Elebro J, Gaber A et al (2014) Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis. PLoS ONE 9:e112728. https://doi.org/10.1371/journal.pone.0112728
doi: 10.1371/journal.pone.0112728 pubmed: 25397670 pmcid: 4232506
Biswas S, Mandal G, Payne KK et al (2021) IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature 591:464–470. https://doi.org/10.1038/s41586-020-03144-0
doi: 10.1038/s41586-020-03144-0 pubmed: 33536615 pmcid: 7969354

Auteurs

Yasuhiro Nagata (Y)

Leading Medical Research Core Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Shinichi Kageyama (S)

Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan. kageyama@med.mie-u.ac.jp.
ORCID: 0000-0002-7682-3295

Takeshi Ishikawa (T)

Department of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Satoshi Kokura (S)

Department of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Tetsuya Okayama (T)

Department of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Tetsuya Abe (T)

Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.

Masahiko Murakami (M)

Division of Gastroenterological and General Surgery, School of Medicine, Showa University, Tokyo, Japan.

Koji Otsuka (K)

Division of Gastroenterological and General Surgery, School of Medicine, Showa University, Tokyo, Japan.

Tomotake Ariyoshi (T)

Division of Gastroenterological and General Surgery, School of Medicine, Showa University, Tokyo, Japan.

Takashi Kojima (T)

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Hospital East, Kashiwa, Japan.

Ken Taniguchi (K)

Department of Surgery, Nagasaki Medical Center, Omura, Japan.

Shinichiro Kobayashi (S)

Department of Surgery, Nagasaki Medical Center, Omura, Japan.

Hideaki Shimada (H)

Department of Gastroenterological Surgery, Toho University Omori Medical Center, Tokyo, Japan.

Satoshi Yajima (S)

Department of Gastroenterological Surgery, Toho University Omori Medical Center, Tokyo, Japan.

Takashi Suzuki (T)

Department of Gastroenterological Surgery, Toho University Omori Medical Center, Tokyo, Japan.

Satoshi Hirano (S)

Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Takahiro Tsuchikawa (T)

Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Toshiaki Shichinohe (T)

Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Shugo Ueda (S)

Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.

Kengo Kanetaka (K)

Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Akira Yoneda (A)

Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Hisashi Wada (H)

Department of Clinical Research in Tumor Immunology, Osaka University Graduate School of Medicine, Suita, Japan.

Yuichiro Doki (Y)

Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.

Hiroki Yamaue (H)

Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.

Masahiro Katsuda (M)

Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.

Masaki Ohi (M)

Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Hiromi Yasuda (H)

Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Ken Kondo (K)

Department of Surgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Masato Kataoka (M)

Department of Surgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Yasuhiro Kodera (Y)

Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Masahiko Koike (M)

Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Taizo Shiraishi (T)

Department of Oncologic Pathology, Mie University Graduate School of Medicine, Tsu, Japan.

Yoshihiro Miyahara (Y)

Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan.

Naoki Goshima (N)

Department of Human Science, Faculty of Human Science, Musashino University, Tokyo, Japan.

Eriko Fukuda (E)

Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.

Kei Yamaguchi (K)

Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.

Eiichi Sato (E)

Department of Pathology (Medical Research Center), Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.

Hiroaki Ikeda (H)

Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Tomomi Yamada (T)

Department of Medical Innovation, Osaka University Hospital, Suita, Japan.

Masaharu Osako (M)

FIVERINGS CO., LTD., Osaka, Japan.

Kaoru Hirai (K)

FIVERINGS CO., LTD., Osaka, Japan.

Hiroshi Miyamoto (H)

FIVERINGS CO., LTD., Osaka, Japan.

Takashi Watanabe (T)

Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan.

Hiroshi Shiku (H)

Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan. shiku@med.mie-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antitumoraux › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes néoplasiques › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins anticancéreux › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du platine › Cisplatine › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Tumeurs gastro-intestinales › Tumeurs de l'oesophage › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Tumeurs gastro-intestinales › Tumeurs de l'oesophage › Carcinome épidermoïde de l'oesophage › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Pyrimidinones › Uracile › Fluorouracil › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Glucides › Polyosides › Glucanes › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline A › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Diagnostic › Pronostic › Prognostic significance of NY-ESO-1 antigen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteur Fc › Récepteur immunoglobuline polymérique › Prognostic significance of NY-ESO-1 antigen...